Profil
Ioana C.
Hone is currently working as an Investor Relations Contact at Lineage Cell Therapeutics, Inc. Previously, she worked as a Director-Investor Relations at LifeVantage Corp., Mast Therapeutics, Inc., and as an Investor Relations Contact at Savara, Inc.
Aktive Positionen von Ioana C. Hone
| Unternehmen | Position | Beginn |
|---|---|---|
| LINEAGE CELL THERAPEUTICS, INC. | Investor Relations Kontakt | - |
Ehemalige bekannte Positionen von Ioana C. Hone
| Unternehmen | Position | Ende |
|---|---|---|
| LIFEVANTAGE CORPORATION | Public Communications Contact | - |
| SAVARA INC. | Investor Relations Kontakt | - |
Mast Therapeutics, Inc.
 Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Investor Relations Kontakt | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| LIFEVANTAGE CORPORATION | Health Technology |
| SAVARA INC. | Health Technology |
| LINEAGE CELL THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Health Technology |
